Engineering iPSC-derived lymphocytes with recombinant Fc?? receptors for enhanced tumor cell targetingby therapeutic antibodies

Project: Research project

Project Details

Description

Engineering iPSC-derived lymphocytes with recombinant Fc?? receptors for enhanced tumor cell targeting by therapeutic antibodies
StatusActive
Effective start/end date10/15/1910/14/21

Funding

  • Fate Therapeutics, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.